Top Tweets for #Datopotamab
Rate response is a great biomarker but duration of response can shows how effective is the drug beyond response @OncoAlert @FernandoOnco #ESMO25 #tropionbreast #datopotamab
ASCENT-03 x Tropion-Breast 02
#sacituzumab x #datopotamab
Who wins? The patient has now 2 options despite differences in trial design
Now 1L TNBC is ADC based in patients without IO indications
TB03 cross over?? 🫠
@OncoAlert @FernandoOnco #ESMO25
In #advanced #UC patients, phase II #TROPIONPanTumor03 study showed promising efficacy of #datopotamab #deruxtecan + #rilvegostomig (1L ORR 68.2% and 2L 38.9% at 12w) w/ manageable safety #DrSunYoungRha
#ESMO25
@TiansterZhang
💊#Datopotamab deruxtecan-dlnk accelerated approval by @US_FDA
➡️Pts: #EGFR mutated #NSCLC
➡️Setting: locally advanced or metastatic
➡️Outcome: ORR 45% and median DOR 6.5 months
➡️Trials: TROPION-Lung 01 and 05
@ChristianRolfo @rolfolab @OSUCCC_James @OncoAlert
🚨🔥@OncoAlert Hot Off The Press
#BigNews
@US_FDA grants #accelerated approval for #Datopotamab for #patients:
✅With locally advanced or metastatic #EGFRm non-small cell #LungCancer.
&
✅ Have received prior #EGFR targeted therapy & prior chemotherapy.
💥Approval is based on #TROPION-Lung05 & #TROPION-Lung01 trials.
⭐️#ORR: 45% #mDOR: 6.5 months
👇🏻
https://t.co/eS78Yv4QB2
#datopotamab ocular and mucositis side effects
New drugs, new side effects @ASCO #ASCO25
Patient education is the key to success @OncoAlert
#TROPIONPanTumor01- #datopotamab #deruxtecan in #heavily #pretreated #mUC showed ORR by BICR 25% and median DFS 6.9m. 76.2% of responders w/response at 6 months & manageable safety profile. Look out for TROPIONPanTumor02 &3 studies! #Dr. Funda Meric-Bernstam @TiansterZhang
#Datopotamab deruxtecan (#DatoDXd) has been granted Priority Review from #FDA for advanced EGFR+ non-small cell #lungcancer (#NSCLC) following prior therapies. Pooled analysis showed a 42% objective response rate and a 7-month MDR #Datopotamabderuxtecan
https://t.co/tzhkDYJEfr
#FDA has approved #Datroway (#datopotamab #deruxtecan-dlnk) for adult patients with unresectable or metastatic HR+, HER2- #breastcancer. This innovative #TROP2-directed antibody-drug conjugate (#ADC) provides a much-needed treatment option for patients
https://t.co/1WbpqZwS2p
🚨🔥@OncoAlert Hot off the press.
Just published @JCO_ASCO
Results of #TROPION/#Lung05 Phase 2 trial of #Datopotamab Deruxtecan in:
Advanced Non–Small Cell #LungCancer
WITH #Actionable #GenomicAlterations WITH progression after #TargetedTherapy AND Chemotherapy.
#ResponseRate:
✅Overall: 36%
✅In #EGFR+: 44%
✅In #ALK+: 24%
Overall #DCR: 79%
👇🏼
https://t.co/q1UES36nqm
AstraZeneca breast cancer drug trial fails to improve overall survival #AZN @AstraZeneca https://t.co/xAaB1RVA8g #investing #shares #voxmarkets via @VOXmarkets
#datopotamab #deruxtecan #breastcancer #clinicaltrial #AstraZeneca
🔥🚨1/2 @OncoAlert Hot off the press.
Just published @JCO_ASCO in conjunction with presentation of overall survival data @IASLC #WCLC2024.
Results of #TROPION-Lung01 Study of #Datopotamab Deruxtecan Vs
Docetaxel for Previously Treated Advanced #NSCLC.
👇🏼
https://t.co/nPtflOJWQK
Keeping up with the press-release literature pre-ASCO24 - @Latinamd
#ASCO24 #Cancer #Datopotamab #Deruxtecan #NSCLC #OncoDaily #Oncology #SylvesterComprehensiveCancerCenter
https://t.co/cqimo2oYIk
Sometimes new agents don't have a better OS but they provide benefits - @LuisRaezMD
@LungAmbition @LUNGevity @GO2forLungCancr @StephenVLiu
#ADC #Cancer #Datopotamab #MemorialCancerInstitute #OncoDaily #Oncology
https://t.co/zlVBSqkdc1
Keeping up with the press-release literature pre-#ASCO24
#TROPION-lung01 #Datopotamab deruxtecan (ADC) showed meaningful (?magnitude) OS advantage vs. chemo in the subgroup of non-squamous NSCLC (but not overall population)
#lcsm 👀following… https://t.co/ia9maehj0c
Application based on results from the TROPION-Lung01 phase 3 trial - @raffcolo
#AntibodyDrug #Cancer #Datopotamab #Deruxtecan #LungCancer #OncoDaily #Oncology
https://t.co/ryaVsWZZ1k
Phase 3 #TROPION-Breast01 trial hits its co-primary endpoint with promising results🎯⚡
💊📊#Datopotamab deruxtecan (DS-1062a) demonstrates a notable improvement in PFS vs chemo in inoperable/metastatic HR+ HER2-low/HER2- cases.
👉https://t.co/sdRUxPK8zy
🔥🚨@OncoAlert Hot off the press, presented @IASLC #WCLC23, results from #TROPION-Lung04 phase 1b Study of #Datopotamab Deruxtecan (Dato-DXd) + #Durvalumab +/-#Carboplatin in Advanced/#NSCLC.
RR in Cohort 2 (doublet): 50%
RR in Cohort 4 (triplet): 77%
No new safety signals.
The first of three Q2 #catalyst stories is here, this one covering big pharma, see the story for the extensive table and commentary: https://t.co/jqN5vXZGF5
Feat. $LLY $MRK $AZN $NVO $DSNKY $RHHBY $JNJ $PFE $BMY #donanemab #Wegovy #Mounjaro #SubQKeytruda #datopotamab
Last Seen Hashtags on Sotwe
Most Popular Users
Elon Musk 
@elonmusk
241.6M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114.2M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
89.9M followers
Taylor Swift
@taylorswift13
83.8M followers
Lady Gaga
@ladygaga
75.3M followers
Virat Kohli
@imvkohli
73.2M followers
Kim Kardashian
@kimkardashian
70.8M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.2M followers
Bill Gates
@billgates
65M followers
Selena Gomez
@selenagomez
63M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers